News | Coronavirus (COVID-19) | April 08, 2020

No Evidence Supporting Discontinuing RAAS Inhibitors in COVID-19 Patients

ACE and ARBs provide benefit to cardiac patients and harm to COVID-19 patients remains unproven

ACE and ARBs provide benefit to cardiac patients and harm to COVID-19 patients remains unproven, NEJM

April 8, 2020 — There has been debate in the past month or so during the novel coronavirus (COVID-19) pandemic whether the renin-angiotensin-aldosterone system (RAAS) inhibitors, such as angiotensin-converting–enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs), should be stopped in COVID-19 patients. An article in the New England Journal of Medicine (NEJM) suggests these medications provide known benefits to patients who need them, while potential harms remain unproven.[1]

RAAS experts have provided a useful special report summarizing the evidence about the use of ACE inhibitors and ARBs, in patients with COVID-19. The data may provide context for the recommendations from several professional groups. The article suggests treatment with RAAS inhibitors should not be changed out of concerns that they might increase or decrease risk in patients with COVID-19, said Harlan M. Krumholz, M.D., director of the Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, who reviewed the article in NEJM Journal Watch.

SARS-CoV-2, the virus that causes COVID-19, enters cells by binding to ACE2 as a receptor. ACE2 counters RAAS activation, primarily by degrading angiotensin II to angiotensin-(1–7), reducing angiotensin II's effects on vasoconstriction, sodium retention, and fibrosis. Some preclinical studies indicated that RAAS inhibitors may increase the expression of ACE2, raising concerns that these medications could increase susceptibility to infection. Nevertheless, whether ACE inhibitors or ARBs harm patients with COVID-19 or, even, are protective against the disease remains unknown. 

However, withdrawing these therapies in patients for whom they are indicated could be expected to increase risks from patients' underlying conditions or from COVID-19 complications. The authors strongly endorse continuing RAAS inhibitors until better evidence suggests otherwise.

 

Related ACE and ARB COVID-19 Content:

COVID-19 Hydroxychloroquine Treatment Brings Prolonged QT Arrhythmia Issues

AHA, ACC, HRS Caution Use of COVID-19 Therapies Hydroxychloroquine and Azithromycin in Cardiac Patients

ESC Council on Hypertension Says ACE-I and ARBs Do Not Increase COVID-19 Mortality

VIDEO: What Cardiologists Need to Know about COVID-19 — Interview with Thomas Maddox, M.D.

Reference:

1. Vaduganathan M et al. Renin–angiotensin–aldosterone system inhibitors in patients with Covid-19. N Engl J Med 2020 Mar 30; [e-pub]. https://doi.org/10.1056/NEJMsr2005760.

 


Related Content

News | Cardiovascular Clinical Studies

November 29, 2023 — Inari Medical, Inc., a medical device company with a mission to treat and transform the lives of ...

Home November 29, 2023
Home
News | Cardiovascular Clinical Studies

November 29, 2023 — Foldax, Inc., a leader in the development of innovative, polymer heart valves, today announced ...

Home November 29, 2023
Home
News | Cardiovascular Clinical Studies

November 28, 2023 — Abiomed, part of Johnson & Johnson MedTech[1], announces the first patient in the world has been ...

Home November 28, 2023
Home
News | Cardiovascular Clinical Studies

November 27, 2023 — Esperion announced the presentation of results from a pre-specified, exploratory analysis of CLEAR ...

Home November 27, 2023
Home
News | Cardiovascular Clinical Studies

November 22, 2023 — The first clinical trial to challenge the routine implantation of a defibrillator in myocardial ...

Home November 22, 2023
Home
News | Cardiovascular Clinical Studies

November 15, 2023 — Researchers at the University of Leicester have discovered the mechanism by which cholesterol in our ...

Home November 15, 2023
Home
News | Cardiovascular Clinical Studies

November 6, 2023 — Bristol Myers Squibb announced that research across the company’s cardiovascular franchise will be ...

Home November 06, 2023
Home
News | Cardiovascular Clinical Studies

October 20, 2023 — JenaValve Technology, Inc., developer and manufacturer of the Trilogy Transcatheter Heart Valve (THV) ...

Home October 20, 2023
Home
News | Cardiovascular Clinical Studies

October 12, 2023 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home October 12, 2023
Home
Subscribe Now